Exlinkibart clinical trials
Also written LVGN6051.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses exlinkibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LVGN6051
- 3
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Lyvgen Biopharma Holdings Limited (4) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Anlotinib (1) · Pradusinstobart (1) · Dalnicastobart (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test exlinkibart.
- Oct 2027A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)Phase 2 · Lyvgen Biopharma Holdings Limited
Studies
Open first, then newest update. How each study uses exlinkibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsTerminatedPhase 1M.D. Anderson Cancer CenterNCT05075993Written as LVGN3616 + LVGN6051 + Nab-Paclitaxel
- A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue SarcomaCompletedPhase 1/2Lyvgen Biopharma Holdings LimitedNCT05301764Written as LVGN6051 and Anlotinib
- A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)Active, not recruitingPhase 2Lyvgen Biopharma Holdings LimitedNCT06378177Written as LVGN6051 Monoclonal Antibody Injection
- Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic MalignancyCompletedPhase 1Lyvgen Biopharma Holdings LimitedNCT04130542Written as LVGN6051
- Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic MalignancyCompletedPhase 1Lyvgen Biopharma Holdings LimitedNCT04694781Written as LVGN6051
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped1
Codes
What other systems call exlinkibart · ClinicalTrials.gg INT014401
- UNII (FDA) 23C7TO9S06EXLINKIBARTOne source FDA
- NCI Thesaurus C171541ExlinkibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 23C7TO9S06 | EXLINKIBART | One source FDA |
| NCI Thesaurus | C171541 | Exlinkibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.